Oncology - Medicine.net

Deep Learning in Cancer: Redefining Diagnosis, Prognosis, and Precision Oncology

Updated on: May 28,2025

Deep Learning in Cancer: Redefining Diagnosis, Prognosis, and Precision Oncology

Updated on:May 28,2025

Why lung cancer doesn't respond well to immunotherapy

by Anne Trafton,Massachusetts Institute of TechnologyA new MIT study explains why dendritic cells (green) in lymph nodes that drain from the lungs fail to stimulate killer T cells (white) to att

Updated on: January 08,2024

Why lung cancer doesn't respond well to immunotherapy

by Anne Trafton,Massachusetts Institute of TechnologyA new MIT study explains why dendritic cells (green) in lymph nodes that drain from the lungs fail to stimulate killer T cells (white) to att

Updated on:January 08,2024

PAD4 inhibition in neutrophils halts cancer progression and metastasis

byThe Wistar InstituteCancer Cell Dividing. Credit: The Wistar InstituteResearchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at Jubilant Therap

Updated on: December 17,2023

PAD4 inhibition in neutrophils halts cancer progression and metastasis

byThe Wistar InstituteCancer Cell Dividing. Credit: The Wistar InstituteResearchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at Jubilant Therap

Updated on:December 17,2023

Novel cell 'switches' found to promote lung cancer growth, treatment resistance

by Melissa Rohman,Northwestern UniversitySCLC cell lines have divergent gene regulatory networks and phenotypes. (A) Hierarchical clustering was performed using 53 SCLC cell lines. Silhouette wi

Updated on: December 21,2023

Novel cell 'switches' found to promote lung cancer growth, treatment resistance

by Melissa Rohman,Northwestern UniversitySCLC cell lines have divergent gene regulatory networks and phenotypes. (A) Hierarchical clustering was performed using 53 SCLC cell lines. Silhouette wi

Updated on:December 21,2023

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

Updated on: December 17,2023

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

Updated on:December 17,2023

Carbon oxide gas boosts photothermal therapy under mild temperature

by ZHANG Nannan,Chinese Academy of SciencesSchematic illustration of (A) synthesis route of mPEG(CO) and (B) the nanobomb consist of mPEG(CO) and PBPTV. (C) Schematic illustration of low-tempera

Updated on: December 22,2023

Carbon oxide gas boosts photothermal therapy under mild temperature

by ZHANG Nannan,Chinese Academy of SciencesSchematic illustration of (A) synthesis route of mPEG(CO) and (B) the nanobomb consist of mPEG(CO) and PBPTV. (C) Schematic illustration of low-tempera

Updated on:December 22,2023

Survival rates high for children, teens with melanoma

by Lori SolomonSurvival rates for children and adolescents with melanomas are high, according to a study published online Dec. 9 in theJournal of the American Academy of Dermatology.Mary-Ann El

Updated on: December 21,2023

Survival rates high for children, teens with melanoma

by Lori SolomonSurvival rates for children and adolescents with melanomas are high, according to a study published online Dec. 9 in theJournal of the American Academy of Dermatology.Mary-Ann El

Updated on:December 21,2023

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25, 2015Jason M. BroderickNivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.Padmanee Sharm

Updated on: October 24,2023

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25, 2015Jason M. BroderickNivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.Padmanee Sharm

Updated on:October 24,2023

“The power of science”: HPV vaccine proven to dramatically reduce cervical cancer

byLilly Matson| Analysis3 November 2021Share this articleAlmost all cervical cancers are caused by the human papilloma virus (HPV), depicted above.After decades of research,the UK im

Updated on: December 19,2023

“The power of science”: HPV vaccine proven to dramatically reduce cervical cancer

byLilly Matson| Analysis3 November 2021Share this articleAlmost all cervical cancers are caused by the human papilloma virus (HPV), depicted above.After decades of research,the UK im

Updated on:December 19,2023

Lung cancer screening guidelines perpetuate racial disparities, study finds

Lung cancer screening guidelines perpetuate racial disparities, study findsby Krista Conger,Stanford UniversityRacial Disparities in the Eligibility-Incidence (E-I) Ratio Through the US Preventi

Updated on: October 30,2023

Lung cancer screening guidelines perpetuate racial disparities, study finds

Lung cancer screening guidelines perpetuate racial disparities, study findsby Krista Conger,Stanford UniversityRacial Disparities in the Eligibility-Incidence (E-I) Ratio Through the US Preventi

Updated on:October 30,2023

Acute leukemia patients treated with common therapy have increased risk for heart failure

byPerelman School of Medicine at the University of PennsylvaniaPatients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heigh